Ocugen price target raised to $8 from $5 at Noble Capital

Noble Capital analyst Robert LeBoyer raised the firm’s price target on Ocugen to $8 from $5 and keeps an Outperform rating on the shares to reflect the company’s recent progress in its clinical programs. Since OCU410 has recently begun clinical trials in dry age-related macular degeneration, or dAMD, the firm has adjusted its view of the probability of market entry, the analyst tells investors.